Cells from people with systemic sclerosis produce less of the enzymes that break down collagen when exposed to TGF-β1, so collagen builds up instead of being cleared, contributing to tissue scarring.
Evidence from Studies
Supporting (1)
Community contributions welcome
Intrinsic Deregulation of Vascular Smooth Muscle and Myofibroblast Differentiation in Mesenchymal Stromal Cells from Patients with Systemic Sclerosis
In people with systemic sclerosis, their repair cells don’t make enough of the enzymes that break down collagen when exposed to a specific signal (TGF-β1), so collagen piles up and causes scarring — and this study shows exactly that.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether reduced MMP-2/MMP-9 response to TGF-β1 in MSCs is a consistent feature across SSc populations and correlates with fibrosis progression.
A systematic review and meta-analysis of all published studies measuring MMP-2 and MMP-9 mRNA or protein expression in MSCs from SSc patients versus controls after TGF-β1 stimulation, with pooled effect sizes and subgroup analysis by disease subtype and fibrosis severity.
Whether restoring MMP-2/MMP-9 expression in SSc-MSCs reduces fibrosis in vivo.
A double-blind RCT of 90 SSc patients with skin fibrosis, randomized to receive autologous MSCs transduced to overexpress MMP-2 or control vector, followed by intravenous infusion; primary outcome is change in mRSS and secondary outcomes include skin collagen content and serum MMP levels.
Whether low MMP-2/MMP-9 response in baseline MSCs predicts future fibrosis progression in early SSc.
A prospective cohort of 160 patients with early SSc, collecting MSCs at diagnosis and measuring MMP-2/MMP-9 mRNA after TGF-β1 stimulation; primary outcome is change in FVC and skin score over 4 years.
Whether MMP-2/MMP-9 suppression in MSCs is more severe in SSc patients with lung fibrosis than those without.
A case-control study comparing TGF-β1-induced MMP-2 and MMP-9 mRNA expression in MSCs from 45 SSc patients with interstitial lung disease and 45 without, matched for disease duration and autoantibody status.
Whether MMP-2/MMP-9 expression in MSCs correlates with current collagen burden in SSc patients.
A cross-sectional analysis of MSCs from 140 SSc patients, measuring MMP-2 and MMP-9 mRNA after TGF-β1 stimulation and correlating with skin biopsy collagen content and serum procollagen III levels.